

Review of: "Targeting Alzheimer's disease hallmarks with the Nrf2 activator Isoeugenol"

Neha Singh

Potential competing interests: No potential competing interests to declare.

Abstract:

Enhance clarity by shortening the background/introduction details in the Abstract. (Tip: divide abstract concisely to include these four points: objective, methods, major findings, and conclusions.)

Introduction:

Condense/Shorten the introduction into four distinct sections: 1) Alzheimer's Disease (AD) and its associated complications, 2) Role of Nrf2, neuroinflammation, and oxidative stress in AD pathophysiology, 3) Isoeugenol, and 4) Study objectives (briefly). Please omit the results from the conclusion of the introduction (to shorten the introduction).

Methods:

Methods are well stated; however, please include the rationale behind the choice of the number of mice in groups and the dose and time of Isoeugenol administrations. Please consider adding a study design (schematic).

Results:

While the results are adequately elucidated, kindly consider presenting them more succinctly.

Discussion:

Shorten the discussion by focusing on key points, discussing study limitations, and proposing future directions for the presented molecule. (Tip for shortening the discussion section: Provide concise comparisons with relevant studies).